近日，上海泽德曼医药科技有限公司与国内儿科巨头、知名上市公司济川药业（600566）股份有限公司 (股票代码600566)签署协议，就泽德曼医药旗下的泽立美在中国(不含港澳台)的独家商业化权益达成合 作。本次合作，泽德曼医药将获得最高1.9亿元首付款及里程碑付款，其中包括最高1.25亿元人民币首付 及非销售相关的近期款项，外加6500万元的研发里程碑付款。 泽德曼医药CEO陈庚辉博士表示，在AhR靶点领域，泽德曼医药始终致力于源头创新，造就了泽立美源 自中国、惠及全球的里程碑式突破。作为该药全球商业化的重要环节，将泽立美中国市场推广和临床普 及交予济川药业，将有助于该产品的国际化进程，实现泽立美创新价值的最大化释放。我们期待携手济 川药业，加速创新药服务更多的患者群体，为皮肤健康贡献更多中国力量。 作为全球领先的深耕芳香烃受体(AhR)及相关疾病治疗药物的创新药企业，泽德曼医药此次与济川药业 的商业化合作，是泽德曼医药在市场拓展布局中的重要里程碑，也是双方资源互补、协同共赢的重要举 措。双方将携手合作，为儿科、皮肤科药物注入新的活力，推动泽立美惠及更多中国患者。 济川药业集团总经理曹伟表示，此次济川药业与泽德 ...

泽立美本维莫德乳膏是泽德曼医药自主研发、具有全新作用机制和靶点的非激素创新药，也是全球 首个被批准用于2岁以上儿童与成人湿疹（特应性皮炎）治疗的芳香烃受体（AhR）调节剂。可通过抑 制炎症、修复皮肤屏障、调节菌群和抗氧化应激发挥治疗作用，具有疗效好、安全性高、复发控制强等 特点，有效解决了传统治疗方案中的疗效有限、副作用多、停药易复发等临床痛点，为儿童及成人湿疹 患者提供了更安全、更有效的治疗选择。2025版《中国特应性皮炎外用治疗与管理专家共识》将泽立美 列为重要治疗选择，该药已入选《2025年度上海市生物医药"新优药械"产品目录》。 泽德曼医药CEO陈庚辉博士表示："我们很高兴与国内儿科与皮肤科领域都有卓越商业化能力的济 川药业合作，此次强强联手，是双方产品协同与资源互补的关键一步。在AhR靶点领域，泽德曼医药始 终致力于源头创新，造就了泽立美®源自中国、惠及全球的里程碑式突破。作为该药全球商业化的重要 环节，将泽立美中国市场推广和临床普及交予济川药业，将有助于该产品的国际化进程，实现泽立美创 新价值的最大化释放。我们期待携手济川药业，加速创新药服务更多的患者群体，为皮肤健康贡献更多 中国力量。" 济川药 ...

济川药业表示，本次交易完成后，公司将进一步加强产品线的丰富程度，有利于公司业务的可持续发 展，符合公司的发展战略和长远利益。 北京商报讯（记者 丁宁）2月26日晚间，济川药业（600566）发布公告称，公司全资子公司济川药业集 团有限公司（以下简称"济川有限"）与上海泽德曼医药科技有限公司（以下简称"泽德曼"）签署独占性 商业化权益协议，泽德曼授权济川有限在合作期限内独家负责其拥有的泽立美本维莫德乳膏在中国大陆 地区（不包含香港、澳门和台湾地区）的商业化。济川有限支付的首付款及里程碑付款将不超过1.9亿 元（含税）。 ...

近期，"大健康产品数字营销领航营"在北京亦庄生物医药园开营，深入剖析医药电商、直播营销、广告 合规等最新监管动态；汇聚了来自抖音、小红书、京东等平台的十多位资深运营专家，共同为医药健康 企业呈现了一场政策与市场、策略与实践深度融合的思想盛宴。华商韬略联合创始人周怡作为唯一一名 财经自媒体受邀参会，分享了财经内容赋能大健康行业的创新路径。 华商韬略联合创始人周怡 本次领航营紧扣"政策合规筑基、平台运营促增、跨界融合破局"三大核心板块，通过专题政策解读、实 战案例剖析、提问答疑互动、圆桌交流研讨等多种形式，系统构建了从政策理解到落地执行的知识体 系，为企业搭建了政策分析、经验共享与资源对接的重要平台，切实助力企业在合规轨道上实现数字营 销的提质增效与创新突破。 政策解读精准导航筑牢行业发展安全线 领航营的政策安全篇，特邀专家解读新政。赛迪研究院产业政策研究所所长王昊聚焦《医药工业数智化 转型实施方案(2025-2030)》，系统阐述了如何以数字化、智能化手段驱动医药产业全面升级。 赛迪研究院产业政策研究所所长王昊 平台实操深度解码搭建增长赋能快车道 平台赋能篇深度聚焦抖音、小红书、京东三大关键阵地实操策略。三大平 ...

Core Insights - The "Digital Marketing Leadership Camp for Health Products" was launched in Beijing, focusing on compliance, platform operation, and cross-industry integration to enhance digital marketing effectiveness and innovation for enterprises [1][2]. Group 1: Event Overview - The event was organized by the China Pharmaceutical News Information Association and aimed to build a knowledge system from policy understanding to practical execution [1]. - It featured government regulatory leaders and experts who provided insights into new policies affecting the pharmaceutical industry, including the "Digital Transformation Implementation Plan for the Pharmaceutical Industry (2025-2030)" [1]. Group 2: Key Discussions - Experts analyzed the "Internet Advertising Management Measures" and the core content of the "Internet Advertising Identifiability Enforcement Guidelines" to clarify compliance requirements for digital marketing [1]. - The event included practical strategies for key platforms like Douyin, Xiaohongshu, and JD, with frontline operators sharing comprehensive methodologies for compliance and operational excellence in the health sector [2]. Group 3: Industry Perspectives - Medical professionals and executives from various companies discussed the transformation of doctors' roles and the importance of building trust in the digital age, emphasizing compliance and effective value delivery [2][3]. - The event facilitated discussions on innovative marketing strategies for prescription drugs, highlighting the importance of trust and commercial flow in driving e-commerce sales [2].

Core Insights - The trend of consumerization in pharmaceutical consumption is leading to increased patient involvement in treatment decisions, with safety and brand reputation becoming the primary considerations when purchasing medications [1] - The innovative non-hormonal drug, Zeli Mei Ben Wei Mo De Cream, is leading the market upgrade in the treatment of atopic dermatitis (eczema) [1] Industry Overview - Approximately 70 million eczema patients in China, with over 90% requiring topical treatments [2] - Traditional treatments have limitations such as limited efficacy, significant side effects, and a tendency for relapse after discontinuation [2] - Zeli Mei is the first globally approved aromatic hydrocarbon receptor modulator for eczema treatment in children over 2 years and adults, addressing the core issues of traditional therapies [2] Clinical Efficacy - Zeli Mei has shown a significant improvement in treatment outcomes, with nearly 60% of patients experiencing deep itch relief after 8 weeks, and over 80% efficacy in children [2] - In a Chinese Phase III clinical trial, 70% of patients remained relapse-free for 10 months after stopping treatment [2] - Clinical cases demonstrate rapid symptom relief, with 73% of pediatric patients showing significant improvement after treatment [3]

Core Insights - The collaboration between Zedman Pharmaceuticals and JD Health aims to provide affordable access to innovative treatments for patients with atopic dermatitis through a promotional campaign during JD's 11.11 shopping festival [1][2] - Zedman’s product, Zeli Mei cream, is the first aromatic receptor innovation drug approved for treating eczema in children over 2 years old and adults, demonstrating a high efficacy rate of 83.9% in clinical trials for children aged 7-11 [1] - The partnership emphasizes a comprehensive health management system that includes prevention, diagnosis, and treatment, enhancing JD Health's supply chain capabilities in dermatological products [1] Summary by Sections Collaboration Details - Zedman Pharmaceuticals and JD Health launched a "Caring for Patients" initiative, allowing patients to purchase Zeli Mei cream for only 10 yuan after receiving a 350 yuan coupon [1] - This initiative is part of a broader strategy to ensure patients have access to innovative treatment options through compliant drug supply channels [1] Product Information - Zeli Mei cream is a non-hormonal treatment for eczema, recognized for its safety and effectiveness, with mild to moderate adverse reactions reported [1] - The product has achieved a dual breakthrough in providing rapid itch relief and long-term skin repair [1] Previous Initiatives - In September, JD Health and Zedman initiated the "Health Escort, Safe Transition" campaign to support seasonal health issues, further expanding their collaboration in the dermatological sector [1] - The partnership leverages JD Health's full-chain capabilities in medical services, testing, diagnosis, and medication [1] Safety and Compliance - Zedman Pharmaceuticals values JD Health's strict identity verification, prescription review, and drug traceability systems, which ensure patient safety and respect for drug distribution regulations [2]

Core Viewpoint - The publication of the "Expert Consensus on the Treatment and Management of Atopic Dermatitis (2025 Edition)" provides standardized clinical application guidance for the innovative drug, Zhilimab Benmodem Cream, specifically for atopic dermatitis treatment in China [1] Group 1: Disease Prevalence and Treatment Options - The prevalence of atopic dermatitis among children in China is reported to be between 10% and 15% [1] - For mild to moderate cases, which account for two-thirds of patients, Zhilimab Benmodem Cream is recommended as an important treatment option based on research data from the Chinese population [1] Group 2: Mechanism and Approval - The aryl hydrocarbon receptor (AhR) is identified as a key mediator in the interaction between environmental factors and immune system components, playing a role in maintaining skin homeostasis and alleviating skin inflammation [1] - Zhilimab Benmodem Cream, developed by Shanghai Zedeman Pharmaceutical Technology Co., Ltd., is approved for the treatment of mild to moderate atopic dermatitis in children aged 2 years and older, with its market launch scheduled for November 2024 [1] Group 3: Consensus Development - The consensus was led by Professor Zhang Jianzhong from Peking University People's Hospital, involving 32 experts from dermatology, allergy, and pediatrics, and was established after four rounds of validation [1] - The consensus references 65 domestic and international research studies to create a standardized topical medication treatment system tailored to Chinese patients [1]

Core Insights - The "Expert Consensus on the Treatment and Management of Atopic Dermatitis (2025 Edition)" has been published, providing standardized clinical application guidance for the innovative drug, Zeli Mei Ben Wei Mo De Ointment [1][2] - Atopic dermatitis (AD) has a prevalence rate of 10%-15% among children in China, making it the leading non-fatal skin disease burden [1] - The consensus emphasizes the importance of Zeli Mei Ben Wei Mo De Ointment as a treatment option for the two-thirds of patients with mild to moderate AD, based on research data from the Chinese population [1][2] Treatment Mechanism - Zeli Mei Ben Wei Mo De Ointment works by inhibiting type 2 inflammatory cytokines and repairing the skin barrier, specifically targeting IL-4/IL-13 induced tight junction damage [2] - Clinical trials indicate that the ointment can reduce and eliminate skin lesions while alleviating itching, with most adverse reactions being mild to moderate [2] Treatment Guidelines - The consensus provides clear guidelines for treating special areas and populations, recommending the use of moderately potent topical medications in sensitive areas to avoid the risk of skin atrophy from long-term corticosteroid use [2] - The dual mechanism of Zeli Mei Ben Wei Mo De Ointment offers unique advantages in addressing the inflammatory responses and barrier defects commonly seen in AD patients in China, particularly for children and those contraindicated for steroids [2] - The publication of the consensus aims to guide medical institutions in standardizing the selection of topical medications for AD, promoting the standardization of AD diagnosis and treatment in China [2]

Core Insights - The 82nd American Academy of Dermatology Annual Meeting showcased significant clinical research data on the efficacy of Zeli Mei Ben Wei Mo De cream for treating atopic dermatitis (AD) in the Chinese population, highlighting its rapid itch relief, long-lasting efficacy, and safety profile [1][6]. Research Core Findings - Rapid Itch Relief: Zeli Mei cream demonstrated significant itch relief starting from day one of treatment, with a notable improvement on day two, showing a -5.2% change in average PP-NRS on day one and -8.0% on day two compared to the placebo group [2]. - Long-term Efficacy Maintenance: A one-year study indicated a high no-recurrence rate of 70% after discontinuation of the cream, showcasing its long-term disease control capabilities [2][4]. Research Details - Study Design: The multi-center, confirmatory clinical study involved 272 patients aged 2 years and older with moderate to severe AD across over 30 locations in China, using a randomized, double-blind, placebo-controlled method [3]. - Baseline Characteristics: The majority of the study population (52.2%) were children aged 2-17 years, with an average body surface area (BSA) of approximately 15%, indicating a wide coverage of age groups and disease severity [3]. - Efficacy Data Analysis: After 8 weeks of treatment, the Zeli Mei group achieved EASI75 and IGA response rates of 54.4% and 46.2%, respectively, significantly higher than the placebo group, demonstrating its effectiveness in improving skin lesions and overall disease control [3]. Safety Analysis - Adverse Reactions Overview: Among 193 patients treated with Zeli Mei cream, common adverse reactions included folliculitis (5.7%), pain (3.1%), and pruritus (3.1%), all classified as mild to moderate, with no severe adverse events reported [5]. - Safety Conclusion: The safety profile of Zeli Mei cream is favorable, indicating its suitability for long-term use [5]. Expert Opinions and Industry Significance - Experts highlighted the promising results of Zeli Mei cream in rapid itch relief and long-term disease alleviation, with a low recurrence rate of 70%, marking a new chapter in non-hormonal treatment for AD [6][7]. - The CEO of Zedman emphasized the global potential of Zeli Mei cream and the company's commitment to innovative drug development, enhancing China's international standing in the field of innovative drug research [7].